![]() Innovation is needed to respond to priority health threats such as pathogens with high pandemic potential or resistance to antibiotics. ![]() Currently, European companies find it difficult to access sufficient public and private funding for the development and scaling up of cutting-edge solutions in health and life sciences. Today, the Commission and the European Investment Bank announce the creation of HERA Invest, a € 100 million top-up to the InvestEU programme, to support research and development (R &D) in the most pressing cross-border health threats, financed by the EU4Health programme.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |